Evogene Story

EVGN -- USA Stock

USD 6.08 0.29 5.01%

Macroaxis Story

As many of us are excited about healthcare space, it is fair to outline Evogene within current market trends. We are going to address the reasons why we are still confident in anticipation of a recovery. The returns on investing in Evogene and the market returns of the last few months appear not sensitive to each other. The proof of persistent technical and fundamental indicators of the company suggests a short-term price swing for institutional investors of Evogene. The stock is still going through an active upward rally.

Published over three months ago

View all stories for Evogene | View All Stories

Our latest technical analysis of Evogene (NASDAQ:EVGN)

The company's average rating is Buy from 2 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Evogene market sentiment investors' perception of the future value of Evogene. Let us look at a few aspects of Evogene technical analysis.

Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Evogene. In general, we focus on analyzing Evogene stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Evogene's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Evogene's intrinsic value. In addition to deriving basic predictive indicators for Evogene, we also check how macroeconomic factors affect Evogene price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Evogene's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Evogene in the context of predictive analytics.

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Evogene. Your research has to be compared to or analyzed against Evogene's peers to derive any actionable benefits. When done correctly, Evogene's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Evogene.

How does Evogene Stands against Peers?

Analyzing Evogene competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Evogene across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.

Check out Evogene Competition Details

How Evogene utilizes its cash?

To perform a cash flow analysis of Evogene, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Evogene is receiving and how much cash it distributes out in a given period. The Evogene cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Evogene Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (16.32 Million)

Closer look at Evogene Variance

Evogene has current Variance of 56.13. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.

Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.

Variance

SUM(RET DEV)²

56.13

SUM	=	Summation notation
RET DEV	=	Actual returns deviation over selected period
N	=	Number of points for the period

Let's now compare Evogene Variance to its closest peers:

EVGN

DMAC

DNLI

	EVGN	56.12696772938153
	EQ	8,207.41
	NK	60.01
	DMAC	25.55
	DNLI	33.76

Over 3 percent rise for Evogene. What does it mean for institutional investors?

Semi variance is down to 21.63. It may entail a possible volatility slide. Evogene is displaying above-average volatility over the selected time horizon. Investors should scrutinize Evogene independently to ensure intended market timing strategies are aligned with expectations about Evogene volatility.

Whereas some other firms under the biotechnology industry are still a bit expensive, Evogene may offer a potential longer-term growth to institutional investors. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Evogene as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Evogene.

About Contributor

Raphi Shpitalnik is a Junior Member of Macroaxs Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time base at the beginning of the pandemic and eventually acquired a real test for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Evogene. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC

Evogene Story

USD 6.08 0.29 5.01%

How does Evogene Stands against Peers?

How Evogene utilizes its cash?

Closer look at Evogene Variance

Over 3 percent rise for Evogene. What does it mean for institutional investors?

About Contributor

Would you like to provide feedback on the content of this article?

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY